Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia

Armstrong, Edward P.; Malone, Daniel C.; McCarberg, Bill; Panarites, Christopher J.; Pham, Sissi V.

doi:10.1185/03007995.2011.562885

Cited by 24 publications

(31 citation statements)

References 69 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two studies assumed that failure to respond to one medication had no effect on responses to subsequent treatment 18,30 . In other studies capturing multiple treatment lines, assumptions made relating to how treatment failure affected subsequent treatment effectiveness and patient utility were not clear 4,16,17,24 . Dose titration varies considerably in neuropathic pain care, across patients and across therapies, and it is a key aspect of overall patient experience 35 .…”

Section: Approaches To Modeling Temporal Sequences Of Eventsmentioning

confidence: 99%

“…The search identified 797 studies, 20 of which met the inclusion criteria. Of the 20 included studies, 14 presented original model structures 4,5,[16][17][18][19][20][21][22][23][24]27,29,30 , and six used existing model structures populated with data and assumptions that differed from those in the original study 3,25,26,[31][32][33] . Herein, where data and scope are compared, we refer to all 20 included studies, but where model type and structural elements are compared, we compare across the 14 original model structures only.…”

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

“…Results in Table 1 suggest that the volume of cost-effectiveness studies in neuropathic pain is increasing; over 50% of the 20 inclusions (11 studies) were published after January 2010 [3][4][5]17,19,20,25,29,[31][32][33] . This may reflect an emergence of new treatments for neuropathic pain, and an increasing need across jurisdictions to demonstrate cost-effectiveness in order to receive reimbursement for these types of therapies.…”

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

“…The second most widely appraised therapy was gabapentin, used in five European studies 5,24,26,30,31 . Seven studies were conducted in North America 17,19,20,22,23,27,30 , where appraisal of pregabalin and gabapentin was common across cost-effectiveness analyses and over time 17,19,20,22,23,27,30 . Duloxetine has been appraised in two North American studies published since 2011 17,20 .…”

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

“…These complexities include: patient and treatment heterogeneity; challenges in understanding how treatments affect health outcomes, in particular HRQoL; and understanding the HRQoL and cost implications of multiple, consecutive lines of often ineffective treatment. In 2013, the National Institute for Health and Care Excellence (NICE) in England and Wales reviewed previous economic analyses in neuropathic pain to inform guidance on pharmacological management of neuropathic pain 5 , and were critical of 'potentially serious limitations' in each of the 13 studies identified 4,[16][17][18][19][20][21][22][23][24][25][26][27] . However, the NICE reviewers were not specific in their criticism 5 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Critchlow

Hirst

Akehurst

et al. 2016

Journal of Medical Economics

View full text Add to dashboard Cite

Objectives: Complexities in the neuropathic-pain care pathway make the condition difficult to manage and difficult to capture in cost-effectiveness models. The aim of this study is to understand, through a systematic review of previous cost-effectiveness studies, some of the key strengths and limitations in data and modeling practices in neuropathic pain. Thus, the aim is to guide future research and practice to improve resource allocation decisions and encourage continued investment to find novel and effective treatments for patients with neuropathic pain. Methods: The search strategy was designed to identify peer-reviewed cost-effectiveness evaluations of non-surgical, pharmaceutical therapies for neuropathic pain published since January 2000, accessing five key databases. All identified publications were reviewed and screened according to pre-defined eligibility criteria. Data extraction was designed to reflect key data challenges and approaches to modeling in neuropathic pain and based on published guidelines. Results: The search strategy identified 20 cost-effectiveness analyses meeting the inclusion criteria, of which 14 had original model structures. Cost-effectiveness modeling in neuropathic pain is established and increasing across multiple jurisdictions; however, amongst these studies, there is substantial variation in modeling approach, and there are common limitations. Capturing the effect of treatments upon health outcomes, particularly health-related quality-of-life, is challenging, and the health effects of multiple lines of ineffective treatment, common for patients with neuropathic pain, have not been consistently or robustly modeled. Conclusions: To improve future economic modeling in neuropathic pain, further research is suggested into the effect of multiple lines of treatment and treatment failure upon patient outcomes and subsequent treatment effectiveness; the impact of treatment-emergent adverse events upon patient outcomes; and consistent and appropriate pain measures to inform models. The authors further encourage transparent reporting of inputs used to inform cost-effectiveness models, with robust, comprehensive and clear uncertainty analysis and, where feasible, open-source modeling is encouraged. ARTICLE HISTORY

show abstract

Section: Approaches To Modeling Temporal Sequences Of Eventsmentioning

confidence: 99%

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Critchlow

Hirst

Akehurst

et al. 2016

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Topical Capsaicin Formulations in the Management of Neuropathic Pain

Schumacher

Pasvankas

2014

Capsaicin as a Therapeutic Molecule

View full text Add to dashboard Cite

Capsaicin and Its Role in Chronic Diseases

Fernandes

Cerqueira

Soares

et al. 2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

A significant number of experimental and clinical studies published in peer-reviewed journals have demonstrated promising pharmacological properties of capsaicin in relieving signs and symptoms of non-communicable diseases (chronic diseases). This chapter provides an overview made from basic and clinical research studies of the potential therapeutic effects of capsaicin, loaded in different application forms, such as solution and cream, on chronic diseases (e.g. arthritis, chronic pain, functional gastrointestinal disorders and cancer). In addition to the anti-inflammatory and analgesic properties of capsaicin largely recognized via, mainly, interaction with the TRPV1, the effects of capsaicin on different cell signalling pathways will be further discussed here. The analgesic, anti-inflammatory or apoptotic effects of capsaicin show promising results in arthritis, neuropathic pain, gastrointestinal disorders or cancer, since evidence demonstrates that the oral or local application of capsaicin reduce inflammation and pain in rheumatoid arthritis, promotes gastric protection against ulcer and induces apoptosis of the tumour cells. Sadly, these results have been paralleled by conflicting studies, which indicate that high concentrations of capsaicin are likely to evoke deleterious effects, thus suggesting that capsaicin activates different pathways at different concentrations in both human and rodent tissues. Thus, to establish effective capsaicin doses for chronic conditions, which can be benefited from capsaicin therapeutic effects, is a real challenge that must be pursued.

show abstract

Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia

Cited by 24 publications

References 69 publications

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Topical Capsaicin Formulations in the Management of Neuropathic Pain

Capsaicin and Its Role in Chronic Diseases

Contact Info

Product

Resources

About